Catalyst Biosciences, INC.: directors' dealings · United States · SEC (Form 4)

About Catalyst Biosciences, INC.

Catalyst Biosciences, Inc. (ticker: CBIO) is a United States-based biopharmaceutical company listed on the NASDAQ market. The company has historically been headquartered in South San Francisco, California, and was founded in 2002. Its business model has long been that of a research-stage biotech rather than a commercial pharmaceutical company: value creation depends primarily on scientific progress, clinical milestones, intellectual property, regulatory feedback, and access to capital. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459023004830/cbio-10k_20221231.htm?utm_source=openai)) Catalyst’s core identity has been built around engineered proteases and protease-based therapeutics designed to address severe unmet medical needs. SEC filings describe a pipeline focused on complement dysregulation and related inflammatory pathways, with programs aimed at restoring complement homeostasis or selectively modulating specific components of the cascade. The company has highlighted complement-related candidates such as improved CFI protease programs and C3/C4b degrader platforms, alongside earlier work in hemostasis and rare bleeding disorders. That evolution shows a company that has repeatedly adapted its pipeline toward differentiated, high-science opportunities in niche disease areas. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459022012877/cbio-10k_20211231.htm?utm_source=openai)) From a competitive standpoint, Catalyst operates in one of the most challenging segments of healthcare: early-stage biotech. Its competitive position is not defined by revenue scale or commercial footprint, but by platform novelty, pipeline optionality, and the potential to generate clinical proof-of-concept. Compared with larger and better-capitalized peers, Catalyst is a much smaller company and therefore more exposed to clinical setbacks, financing needs, and strategic resets. For investors, this makes CBIO a highly event-driven equity, with upside driven by data readouts and downside linked to development risk and dilution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459022012877/cbio-10k_20211231.htm?utm_source=openai)) Historically, the company’s operations have been concentrated in South San Francisco, a major biotech cluster in the United States, which supports talent acquisition and proximity to the broader life-sciences ecosystem. Public disclosures also show that the company has used SEC filings and corporate updates to communicate strategic changes, including financing events and ongoing portfolio adjustments. More recently, publicly available filings and insider-transaction disclosures indicate continued corporate activity around governance and ownership changes, reinforcing the view that investors should monitor SEC Form 4s, 8-Ks, and pipeline updates closely. In short, Catalyst Biosciences remains a small-cap NASDAQ biotech with a science-led story, a narrow operating base, and a valuation that is likely to remain highly sensitive to news flow. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1124105/000156459023004830/cbio-10k_20221231.htm?utm_source=openai))